<DOC>
	<DOC>NCT02045472</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacokinetics of single escalating doses of VIS410 in healthy volunteers.</brief_summary>
	<brief_title>A Study of VIS410 to Assess Safety and Pharmacokinetics</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Healthy volunteers Body mass index between 18 and 33 kg/m2, inclusive Normal labs Volunteers agree to use acceptable contraceptive measures Prior receipt of antibody or biologic therapy History of cancer, heart disease, diabetes, respiratory condition (eg asthma), autoimmune disorder, blood dyscrasias Any chronic condition requiring daily prescription or over the counter medication History of a previous severe allergic reaction Drug or alcohol abuse within previous 12 months Positive serology for human immunodeficiency virus (HIV) antibody, hepatitis C virus (HCV) antibody or hepatitis B surface antigen (HBsAg) Positive pregnancy test Breast feeding Positive drug or alcohol test at screening or checkin Receipt of licensed vaccine (within 30 days) or other investigational product within 30 days or 5 halflives, whichever is longer, before study product administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Monoclonal antibody</keyword>
</DOC>